{
    "root": "303d0346-1871-1ced-e063-6394a90a3a1b",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Paroxetine",
    "value": "20250313",
    "ingredients": [
        {
            "name": "ANHYDROUS DIBASIC CALCIUM PHOSPHATE",
            "code": "L11K75P92J",
            "chebi_id": null
        },
        {
            "name": "ANHYDROUS LACTOSE",
            "code": "3SY5LH9PMK",
            "chebi_id": null
        },
        {
            "name": "HYPROMELLOSES",
            "code": "3NXW29V3WO",
            "chebi_id": null,
            "drugbank_id": "DB11075"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "chebi_id": null,
            "drugbank_id": "DB14077"
        },
        {
            "name": "POLYETHYLENE GLYCOL 6000",
            "code": "30IQX730WE",
            "chebi_id": null,
            "drugbank_id": "DB11161"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2",
            "chebi_id": null
        },
        {
            "name": "POVIDONE",
            "code": "FZ989GH94E",
            "chebi_id": null,
            "drugbank_id": "DB11061"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": null,
            "drugbank_id": "DB09511"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": null,
            "drugbank_id": "DB09536"
        },
        {
            "name": "PAROXETINE HYDROCHLORIDE HEMIHYDRATE",
            "code": "X2ELS050D8",
            "chebi_id": null
        }
    ],
    "indications": [
        {
            "text": "paroxetine tablets indicated adults treatment : major depressive disorder ( mdd ) obsessive compulsive disorder ( ocd ) panic disorder ( pd ) social anxiety disorder ( sad ) generalized anxiety disorder ( gad ) posttraumatic stress disorder ( ptsd )",
            "doid_id": null,
            "orphanet_entities": []
        }
    ],
    "contraindications": [
        {
            "text": "recommended starting maximum daily mdd , ocd , pd , ptsd : ( 2.2 ) indication starting daily dose maximum daily dose mdd 20 mg 50 mg ocd 20 mg 60 mg pd 10 mg 60 mg ptsd 20 mg 50 mg recommended starting sad gad 20 mg daily . ( 2.3 ) elderly patients , patients severe renal impairment severe hepatic impairment : starting 10 mg daily . maximum 40 mg daily . ( 2.4 ) discontinuing paroxetine tablets , reduce gradually . ( 2.6 , 5.7 )",
            "doid_id": null,
            "orphanet_entities": [
                {
                    "disease": "severe hepatic impairment",
                    "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_447788"
                },
                {
                    "disease": "severe renal impairment",
                    "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_447788"
                }
            ]
        }
    ],
    "warningsAndPrecautions": "paroxetine tablets usp , 30 mg white off-white , round-shaped , biconvex , film-coated tablets debossed logo 'zc17 ' one side plain side , supplied follows : ndc : 70518-2465-00 ndc : 70518-2465-01 ndc : 70518-2465-02 ndc : 70518-2465-03 packaging : 30 1 blister pack packaging : 90 1 bottle plastic packaging : 90 1 bottle plastic packaging : 30 1 blister pack store 20\u00b0c 25\u00b0 c ( 68\u00b0f 77\u00b0 f ) [ usp controlled room temperature ] . repackaged distributed : remedy repack , inc. 625 kolter dr. suite # 4 indiana , pa 1-724-465-8762",
    "adverseReactions": "paroxetine tablets contraindicated patients : taking , within 14 days stopping , maois ( including maois linezolid intravenous methylene blue ) increased risk serotonin syndrome [ ( 5.2 ) , ( 7 ) ] . taking thioridazine risk qt prolongation [ ( 5.3 , ( 7 ) ] taking pimozide risk qt prolongation [ ( 5.3 ) , ( 7 ) ] . known hypersensitivity ( e.g . , anaphylaxis , angioedema , stevens-johnson syndrome ) paroxetine inactive ingredients paroxetine tablets [ ( 6.1 ) , ( 6.2 ) ] .",
    "indications_original": "Paroxetine tablets are indicated in adults for the treatment of:\n                  \n                     Major depressive disorder (MDD)\n                     Obsessive compulsive disorder (OCD)\n                     Panic disorder (PD)\n                     Social anxiety disorder (SAD)\n                     Generalized anxiety disorder (GAD)\n                     Posttraumatic stress disorder (PTSD)",
    "contraindications_original": "Recommended starting and maximum daily dosage for MDD, OCD, PD, and PTSD: ( 2.2 ) Indication Starting Daily Dose Maximum Daily Dose MDD 20 mg 50 mg OCD 20 mg 60 mg PD 10 mg 60 mg PTSD 20 mg 50 mg Recommended starting dosage for SAD and GAD is 20 mg daily. ( 2.3 ) Elderly patients, patients with severe renal impairment or severe hepatic impairment: Starting dosage is 10 mg daily. Maximum dosage is 40 mg daily. ( 2.4 ) When discontinuing paroxetine tablets, reduce dosage gradually. ( 2.6 , 5.7 )",
    "warningsAndPrecautions_original": "Paroxetine Tablets USP, 30 mg are white to off-white, round-shaped, biconvex, film-coated tablets debossed with the logo of 'ZC17' on one side and plain on other side, and\n                  are supplied as follows:\n                  \n                  NDC: 70518-2465-00\n                  NDC: 70518-2465-01\n                  NDC: 70518-2465-02\n                  NDC: 70518-2465-03\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  PACKAGING: 90 in 1 BOTTLE PLASTIC\n                  PACKAGING: 90 in 1 BOTTLE PLASTIC\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  \n                  Store at 20\u00b0C to 25\u00b0 C (68\u00b0F to 77\u00b0 F) [See USP Controlled Room Temperature].\n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions_original": "Paroxetine tablets are contraindicated in patients:\n                  \n                     Taking, or within 14 days of stopping, MAOIs (including the MAOIs linezolid and intravenous methylene blue) because of an increased risk of serotonin syndrome\n  \n   [see Warnings and Precautions (\n   \n    5.2), Drug Interactions (\n   \n    7)].\n  \n   \n                     \n                     Taking thioridazine because of risk of QT prolongation\n  \n   [see Warnings and Precautions (\n   \n    5.3, Drug Interactions (\n   \n    7)]\n  \n   \n                     \n                     Taking pimozide because of risk of QT prolongation\n  \n   [see Warnings and Precautions (\n   \n    5.3), Drug Interactions (\n   \n    7)].\n  \n   \n                     \n                     With known hypersensitivity (e.g., anaphylaxis, angioedema, Stevens-Johnson syndrome) to paroxetine or any of the inactive ingredients in paroxetine tablets [\n  \n   see Adverse Reactions (\n   \n    6.1), (\n   \n    6.2)].",
    "drug": [
        {
            "name": "Paroxetine",
            "drugbank_id": "DB00715"
        }
    ]
}